Mechanisms of traditional Chinese medicine in enhancing the efficacy and reducing the toxicity of immune checkpoint inhibitors via regulation of the tumor microenvironment and gut microbiota.

If you or a loved one is undergoing cancer immunotherapy, you may have heard about immune checkpoint inhibitors (ICIs) — a powerful class of drugs that help the immune system recognize and attack cancer cells. While these treatments can be remarkably effective, they also come with significant challenges, including drug resistance (where the cancer stops responding to treatment) and serious side effects called immune-related adverse events, which can affect organs like the gut and heart.

A new review published in the Journal of Enzyme Inhibition and Medicinal Chemistry explored how Traditional Chinese Medicine (TCM) — including herbal formulas, individual herbs, and concentrated plant compounds — might work alongside immunotherapy to make it more effective and safer.

Researchers found that TCM appears to work through several important pathways. First, it may help reshape the tumor microenvironment — essentially the ecosystem surrounding a tumor — making it less hospitable to cancer and more responsive to immunotherapy drugs. Second, TCM was found to positively influence the gut microbiome, the community of bacteria living in the digestive system that plays a surprisingly large role in how well immunotherapy works. Third, specific herbal compounds were shown to reduce two of the most serious side effects of ICIs: colitis (gut inflammation) and myocarditis (heart inflammation).

For patients, this research suggests that integrating TCM with conventional cancer immunotherapy — under careful medical supervision — may offer a meaningful way to improve treatment outcomes while reducing harmful side effects. The study highlights that TCM's holistic, individualized approach to treatment could complement the precision of modern oncology.

While this research is promising, it is important to work with a licensed, experienced TCM practitioner who has specific training in oncology support and can coordinate care with your medical team.

This review investigates the mechanistic basis by which Traditional Chinese Medicine (TCM) — encompassing single herbs, compound formulas, and bioactive monomers — may potentiate immune checkpoint inhibitor (ICI) efficacy while mitigating immune-related adverse events (irAEs). As a narrative review, the study does not report original sample sizes or effect sizes, but synthesizes existing preclinical and clinical evidence across multiple mechanisms. Key findings indicate that TCM modulates the tumor immune microenvironment (TIME) by promoting M1 macrophage polarization, enhancing CD8+ T-cell infiltration, and downregulating immunosuppressive pathways. TCM also favorably shifts gut microbiota composition, which is increasingly recognized as a determinant of ICI response. Notably, specific herbal interventions demonstrated attenuation of ICI-induced colitis and myocarditis. The authors advocate for syndrome-differentiated, integrative protocols and call for future mechanistic trials to define optimal combination strategies. Clinical takeaway: TCM warrants serious consideration as an adjunctive modality in integrative oncology, particularly for patients experiencing ICI resistance or significant irAEs.